Alex De Windt, MD, Mph
About Alex De Windt, MD, Mph
Alex De Windt, MD, MPH, serves as the Vice President of Drug Safety at Ardelyx, Inc. He has over two decades of experience in the pharmaceutical industry, holding various leadership roles in drug safety and medical affairs across multiple organizations.
Current Role at Ardelyx
Alex De Windt serves as the Vice President of Drug Safety at Ardelyx, Inc. since 2022. In this role, he oversees drug safety operations and ensures compliance with regulatory standards. His position involves collaborating with various departments to enhance product safety and efficacy. He is based in Waltham, Massachusetts.
Previous Experience in Drug Safety and Medical Affairs
Prior to his current role, Alex De Windt held several key positions in the pharmaceutical industry. He worked at Leap Therapeutics as Head of Pharmacovigilance from 2020 to 2022. He also served as Director of Medical & Safety Services at Icon Clinical Research from 2007 to 2012. His experience includes roles at i3 Research as Associate Director from 2003 to 2006, and at Bristol-Myers Squibb as Sr. Manager in Medical Affairs from 2000 to 2002.
Education and Qualifications
Alex De Windt earned his Medical Doctor degree from Eugenio Maria De Hostos University. He also holds a Master of Public Health (MPH) from the University of New England. Additionally, he completed training at Grady Memorial Hospital, further enhancing his medical expertise.
Experience in Contract Research Organizations
With over two decades of experience, Alex De Windt has worked extensively in Contract Research Organizations (CROs). His roles have included Principal Investigator and Medical Monitor, where he has contributed to various clinical trials and research initiatives. His experience spans multiple organizations, including Covance, where he served as Assistant Medical Director from 1996 to 1997.
Expertise in Regulatory Approvals and Product Development
Alex De Windt has a strong background in navigating the global regulatory approvals process. He has worked with international health regulatory agencies, ensuring compliance and facilitating the approval of drug products. His expertise also includes leading cross-functional Research and Development (R&D) teams, contributing to successful product development programs.